Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-875-1 | CAS number: 128-03-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2003
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP - Guideline study, tested with the source substance sodium dimethyldithiocarbamate (CAS No. 128-04-1). In accordance to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on an read-across substance
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Sodium dimethyldithiocarbamate
- EC Number:
- 204-876-7
- EC Name:
- Sodium dimethyldithiocarbamate
- Cas Number:
- 128-04-1
- IUPAC Name:
- sodium dimethyldithiocarbamate
- Details on test material:
- - Name of test material (as cited in study report): SDDC
- Purity: 41.44%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Ltd, Margate, Kent, UK
- Age at study initiation: 5-8 weeks (at start of treatment)
- Weight at study initiation: 164-217 g (♂) and 143-193 g (♀)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
24.4, 122, 610 mg testmaterial/kg/day (incorporating a correction factor for 41% purity; equivalent to 10, 50, 250 mg active ingredients/kg/day)
Basis:
other: nominal in vehicle
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Dose volume: 5 mL/kg bw
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Immediately before dosing and one and five hours after dosing (working week). Immediately before dosing and one hour after dosing at weekends and public holidays.
BODY WEIGHT: Yes
- On Day 0 and then once weekly. Also recorded at terminal kill.
FOOD AND WATER CONSUMPTION: Yes
- Once weekly.
OPHTHALMOSCOPIC EXAMINATION: Yes
- For control and high-dose animals at pre-test and during week 12.
HAEMATOLOGY: Yes
- On Day 90. Where necessary repeated on Day 91.
- Parameters: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelet count, reticulocyte count, total leucocyte count, differential leukocyte count, thromboplastin time (= prothrombin time), activated partial thromboplastin time
CLINICAL CHEMISTRY: Yes
- On Day 90. Where necessary repeated on Day 91.
- Parameters: glucose, urea, creatinine, total bilirubin, total cholesterol, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, calcium, phosphorus, sodium, potassium, chloride, albumin, total protein, albumin/globulin ratio, cholinesterase
NEUROBEHAVIOURAL EXAMINATION: Yes
- Behavioural assessments prior to start of treatment, then once weekly.
Parameters: gait, tremors, twitches, convulsions, bizarre/abnormal/stereotypic behaviour, salivation, pilo-erection, exophthalmia, lachrymation, hyper/hypothermia, skin colour, respiration, palpebral closure, urination, defaecation, transfer arousal, tail elevation
- Functional performance tests
Forelimb/hindlimb grip strength and motor activity were assessed during week 12.
- Sensory Reactivity during week 12.
Parameters: grasp response, vocalisation, toe pinch, tail pinch, finger approach, touch escape, pupil reflex, startle reflex (using ST1058 startle test meter from Benwick Electronics), blink reflex - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Organs: brain, heart, liver, spleen, thymus, kidneys, adrenals, uterus, testes, epididymides, ovaries
HISTOPATHOLOGY: Yes
- all dose groups
- The following tissues were removed from all animals and preserved in buffered 10% formalin:
adrenals, aorta (thoracic), bone & bone marrow (sternum, femur including stifle joint), brain (cerebrum, cerebellum, pons), caecum, colon, duodenum, epididymides, eyes (fixed in Davidson's fluid), gross lesions, heart, ileum with Peyer’s patches, jejunum, kidneys, liver, lungs with bronchi (inflated with formalin before immersion in fixative), lymph nodes (cervical, mesenteric), mammary glands, oesophagus, ovaries, pancreas, pituitary, prostate, rectum, salivary glands (submaxillary), sciatic nerve, seminal vesicles, skeletal muscle, skin (hind limb), spinal cord (cervical, mid-thoracic, lumbar), spleen, stomach, testes, thymus, thyroid/parathyroid, tongue, trachea, urinary bladder, uterus - Statistics:
- Data were processed to give group mean values and standard deviations where appropriate.
- Haematological; blood chemical, organ weight (absolute and relatie to terminal bodyweight), weekly bodyweight gain and quantitative functional performanceand sensory reactivity data were assessed for control and test material treatment groups for dose response relationships by linear regression analysis followed one way analysis variance (ANOVA) incorporating Levene’s test for homogeneity of variance.
- Where variances were shown to be homogenous pairwise comparisons were conducted using Dunnett’s test.
- Where Levene’s test showed unequal variances the data were analysed using non-parametric methods: Kruskal-Wallis ANOVA and Mann-Whitney ‘U’ test.
- For histopathological data chi squared analysis was used for differences in the incidence of lesions occurring with an overall frequency of 1 or greater and Kruskal-Wallis one way non-parametric analysis of variance for the comparison of severity grades for the more frequently observed graded conditions.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Increased salivation of short duration were detected in either sex treated with 250 mg/kg/day together with associated findings of soiled body fur, accompanied in females from Day 28 by infrequent episodes of hunched posture and tiptoe gait. Instances of transient increased salivation were also seen in either sex treated with 50 mg/kg/day.
Excessive visible salivation and findings associated with abdominal discomfort are commonly reported following the oral administration of a test material and are considered to be attributable to the repeated administration of an unpalatable or locally irritant test material formulation by gavage rather than an indication of systemic toxicity.
No death.
BODY WEIGHT AND WEIGHT GAIN
No treatment-related adverse effects on bodyweight development.
FOOD & WATER CONSUMPTION
Reduced food consumption in the high-dose group of either sex was clearly related to the reduced bodyweight. Food efficiency (bodyweight/dietary uptake) was also reduced, indicating impaired food utilisation.
Daily visual inspection of water bottles revealed no overt intergroup differences.
OPHTHALMOSCOPIC EXAMINATION
No treatment-related ocular effects.
HAEMATOLOGY
A clear haemolytic effect was identified for animals of both sexes treated with 50 and 250 mg/kg/day accompanied by an increase in mean corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV). Males also showed a slight increase in mean corpuscular haemoglobin concentration (MCHC) at 250 mg/kg/day.
CLINICAL CHEMISTRY
Increases in plasma levels of total protein, sodium and cholesterol were found in males treated with 250 mg/kg/day.
Females treated with 250 mg/kg/day or animals of either sex treated with lower doses revealed no intergroup differences.
NEUROBEHAVIOUR
- Behavioural assessments
Detailed open-field observations from the fourth week of treatment confirmed the clinical signs of hunched posture and tiptoe gait detected in 250 mg/kg/day females. No treatment-related effects were detected at 50 or 10 mg/kg/day.
- Functional performance tests
Changes in total activity in male rats treated with 50 and 250 mg/kg/day were considered to be an indirect effect of abdominal discomfort associated with the irritancy of the test material formulation.
- Sensory reactivity assessments
Changes were considered to be associated with abdominal discomfort resulting from the irritancy of the test material formulation.
ORGAN WEIGHTS
Increases in kidney, liver and spleen weight when expressed relative to body weight were evident in both sexes treated with 250 mg/kg/day. Females also showed an increase in absolute spleen weight.
GROSS PATHOLOGY
Treatment-related gastric changes were detected in the majority of male animals treated with 250 mg/kg/day.
HISTOPATHOLOGY
- Spleen: Increased extramedullary haemopoiesis: ♂ at all doses/ ♀ at 250 mg/kg/day
Increased haemosiderin deposition in female dosed at 50 mg/kg/day
- Kidneys: Increased haemosiderin deposition: ♂ at 50 and 250 mg/kg/day / ♀ at 250 mg/kg/day
- Urinary Bladder: Indications for hyperplasia of the transitional epithelium in males at 250 mg/kg/day
- Thyroids: Increased follicular cell hypertrophy and associated colloid depletion in males at 250 mg/kg/day
- Stomach: Acanthosis and hyperkeratosis of forestomach epithelium: ♂ at 50 and 250 mg/kg/day / ♀ at 250 mg/kg/day
- Duodenum: Mucosal hypertrophy at 250 mg/kg/day in males was considered to be treatment-related
- Salivary Glands: Atrophy of the serous acini of the submaxillary salivary glands: ♂ / ♀ at 250 mg/kg/day
- Bone marrow: Indirect indication of bone marrow hyperplasia in females at 250 mg/kg/day and 50 mg/kg/day
All findings not described above were considered to be within the range of background lesions which may be recorded in rats of this strain and age.
Effect levels
open allclose all
- Dose descriptor:
- LOAEL
- Effect level:
- 122 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: = 112 mg KDDC (50% solution as supplied)/kg bw/day, based on impaired functional performance, haemolysis, haemosiderosis in spleen and kidney
- Dose descriptor:
- NOAEL
- Effect level:
- 24.4 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: = 22.5 mg KDDC (50% solution as supplied)/kg bw/day
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 7.5.1 -A1 Results of haematology and blood chemistry (after 90 days) |
|
||||||||||
Parameter |
Control |
10 mg/kg |
50 mg/kg |
250 mg/kg |
Dose-response +/– |
||||||
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
||
Number of animals examined |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|||
Haematology |
|||||||||||
RBC count |
– |
– |
– |
– |
– |
– |
↓ |
↓ |
+ |
+ |
|
MHC |
– |
– |
– |
– |
↑ |
↑ |
↑ |
↑ |
+ |
+ |
|
MCV |
– |
– |
– |
– |
↑ |
↑ |
↑ |
↑ |
+ |
+ |
|
MCHC |
– |
– |
– |
– |
– |
– |
↑ |
– |
+ |
– |
|
Blood chemistry |
|||||||||||
Total protein |
– |
– |
– |
– |
– |
– |
↑ |
– |
+ |
– |
|
Na+ |
– |
– |
– |
– |
– |
– |
↑ |
– |
+ |
– |
|
Cholesterol |
– |
– |
– |
– |
– |
– |
↑ |
– |
+ |
– |
|
↑, ↓: statistically significant increase and decrease, respectively |
|
Table 7.5.1 -A2 Results of repeated dose toxicity study (after 90 days) |
|
|||||||||||
Parameter |
Control |
10 mg/kg |
50 mg/kg |
250 mg/kg |
Dose-response +/– |
|||||||
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
|||
Number of animals examined |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Organ weights |
||||||||||||
Kidney, rel. |
– |
– |
– |
– |
– |
– |
↑ |
↑ |
+ |
+ |
||
Liver, rel. |
– |
– |
– |
– |
– |
– |
↑ |
↑ |
+ |
+ |
||
Spleen, rel. |
– |
– |
– |
– |
– |
– |
↑ |
↑ |
+ |
+ |
||
Spleen, abs. |
– |
– |
– |
– |
– |
– |
– |
↑ |
– |
+ |
||
Gross necropsy |
||||||||||||
Stomach – non glandular region thickened |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
3 |
+ |
+ |
||
Stomach – non glandular region sloughing |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
2 |
+ |
+ |
||
Histopathology |
||||||||||||
Spleen, |
1 |
0 |
6 |
0 |
6 |
3 |
9 |
8 |
+ |
+ |
||
Spleen, |
moderate |
2 |
6 |
4 |
7 |
7 |
9 |
9 |
1 |
+ |
+ |
|
marked |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
8 |
||||
Kidneys, |
minimal |
0 |
7 |
2 |
9 |
5 |
6 |
4 |
3 |
– |
+ |
|
slight |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
5 |
||||
Urinary Bladder, |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
2 |
+ |
+ |
||
Thyroids, |
1 |
1 |
0 |
0 |
1 |
1 |
4 |
2 |
+ |
– |
||
Stomach, |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
7 |
+ |
+ |
||
Stomach, |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
5 |
+ |
+ |
||
Duodenum, |
0 |
0 |
1 |
0 |
2 |
0 |
4 |
1 |
+ |
– |
||
Salivary Glands, |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
7 |
+ |
+ |
||
Bone marrow, |
1 |
7 |
0 |
4 |
0 |
2 |
1 |
1 |
– |
+ |
||
a number of animals affected
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.